Growth signaling aberrations, epigenetic dysregulation, and disruption of cell fate determination define the somatic mutational profile of our patient's tumor, which includes mutations in PIK3R1, KMT2D, and NOTCH1. This evidence concerns the gene NOTCH1 and neoplasm.